.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,805,854

« Back to Dashboard

Details for Patent: 6,805,854

Title: Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
Abstract:The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing sumatriptan, frovatriptan, or naratriptan that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of sumatriptan, frovatriptan, or naratriptan. In a method aspect of the present invention, one of sumatriptan, frovatriptan, or naratriptan is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of sumatriptan, frovatriptan, or naratriptan, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering sumatriptan, frovatriptan, or naratriptan through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of sumatriptan, frovatriptan, or naratriptan; and, b) a device that forms a sumatriptan, frovatriptan, or naratriptan aerosol from the composition, for inhalation by the mammal.
Inventor(s): Hale; Ron L. (Woodside, CA), Rabinowitz; Joshua D. (Mountain View, CA), Solas; Dennis W. (San Francisco, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Molecular Delivery Corporation (Palo Alto, CA)
Filing Date:May 22, 2002
Application Number:10/155,705
Claims:1. A composition for delivery of sumatriptan, frovatriptan, or naratriptan comprising a condensation aerosol a) formed by volatilizing sumatriptan, frovatriptan, or naratriptan under conditions effective to produce a heated vapor of the sumatriptan, frovatriptan, or naratriptan and condensing the heated vapor of the sumatriptan, frovatriptan, or naratriptan to form condensation aerosol particles, b) wherein said condensation aerosol particles are characterized by less that 5% sumatriptan, frovatriptan, or naratriptan degradation products, and c) wherein the aerosol MMAD is less than 3 microns.

2. The composition according to claim 1, wherein the condensation aerosol particles comprise at least 90 percent by weight of sumatriptan, frovatriptan, or naratriptan.

3. The composition according to claim 2, wherein the condensation aerosol has a mass median aerodynamic diameter less than 2 microns.

4. The aerosol according to claim 3, wherein the condensation aerosol particles comprise at least 95 percent by weight of sumatriptan, frovatriptan, or naratriptan.

5. A method of producing sumatriptan, frovatriptan, or naratriptan in an aerosol form comprising: a) volatilizing sumatriptan, frovatriptan, or naratriptan under conditions effective to produce a heated vapor of sumatriptan, frovatriptan, or naratriptan, and b) during said volatilizing, passing air through the heated vapor to produce aerosol particles of sumatriptan, frovatriptan, or naratriptan comprising less than 5% sumatriptan, frovatriptan, or naratriptan degradation products and an aerosol having an MMAD less than 3 .mu.m.

6. The method according to claim 5, wherein the aerosol particles are formed at a rate of greater than 0.5 mg/sec.

7. The method according to claim 5, wherein the said volatilizing includes heating a thin layer which includes the sumatriptan, frovatriptan, or naratriptan and which is on a solid support having the surface texture of a metal foil, to a temperature sufficient to volatilize the sumatriptan, frovatriptan, or naratriptan from the thin layer.

8. The method according to claim 5, wherein the aerosol particles comprise at least 90 percent by weight of sumatriptan, frovatriptan, or naratriptan.

9. The method according to claim 8, wherein the aerosol has a mass median aerodynamic diameter less than 2 microns.

10. The method according to claim 9, wherein the aerosol particles comprise at least 95 percent by weight of sumatriptan or naratriptan.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc